Source-grounded facts extracted from Personalis, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Personalis, Inc. updated its first quarter ended March 31, 2026 guidance (reaffirmed).
“On May 7, 2026, Personalis, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026. The full text of the press release is furnished as Exhibit 99.1 to this report on Form 8-K and is incorporated herein by reference.”
Personalis, Inc. reported first quarter of 2024 ended March 31, 2024 results: revenue total company revenue of $19.5 million, net income Net loss of $13.0 million. Guidance raised.
“delivered in Q1, reflecting 100% engagement of NeXT Personal Dx early access clients and strong NeXT Dx growth. “We began 2024 with strong execution as we delivered revenue of $19.5 million in the first quarter, exceeding the upper-end of our guidance range, and we continue to develop compelling NeXT Personal clinical evidence as we work towards obtaining Medicare”
Personalis, Inc. reported financial results for the full year ended December 31, 2023.
“Personalis, Inc. issued a press release announcing its financial results for the quarter and fiscal year ended December 31, 2023”
Personalis, Inc. reported financial results for the fourth quarter ended December 31, 2023.
“Personalis, Inc. issued a press release announcing its financial results for the quarter and fiscal year ended December 31, 2023”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.